By Christopher Robertson Speaking yesterday at America’s Health Insurance Plans’ (AHIP) National Health Policy Conference, FDA Commissioner Scott Gottlieb railed against patient cost-exposure (e.g., copays). His prepared speech said: Patients shouldn’t be penalized by their biology if they need a drug that isn’t on formulary. Patients shouldn’t face exorbitant out of pocket costs, and pay money…
Will Value-based Care Save the Health Care System? March 2, 2018 9:00 AM – 5:00 PM Wasserstein Hall, Milstein East ABC (2036) Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to…
Will Value-based Care Save the Health Care System? March 2, 2018 9:00 AM – 5:00 PM Wasserstein Hall, Milstein East ABC (2036) Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to…
Will Value-based Care Save the Health Care System? March 2, 2018 9:00 AM – 5:00 PM Wasserstein Hall, Milstein East ABC (2036) Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to…
By Mason Marks FDA Commissioner Scott Gottlieb issued a statement on Tuesday about the controversial plant Mitragyna speciosa, which is also known as kratom. According to Gottlieb, kratom poses deadly health risks. His conclusion is partly based on a computer model that was announced in his recent statement. The use of simulations to inform drug…
Will Value-based Care Save the Health Care System? March 2, 2018 9:00 AM – 5:00 PM Wasserstein Hall, Milstein East ABC (2036) Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to…
By Rachel Sachs Yesterday, Alex Azar was sworn in as the Secretary for the Department of Health and Human Services. A key question is whether Azar will take action against high drug prices, and if so, what he will do. At his confirmation hearing, Azar stated clearly that “drug prices are too high.” And during…
By Christopher Robertson and Kelly McBride Folkers In 2014, Arizonans overwhelmingly voted in favor of a ballot referendum that claimed to allow terminally ill patients the “right to try” experimental drugs that have not yet been approved by the Food and Drug Administration (FDA). Despite the policy’s broad support, it has yet to help a…
Will Value-based Care Save the Health Care System? March 2, 2018 9:00 AM – 5:00 PM Wasserstein Hall, Milstein East ABC (2036) Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to…
By Jean-Christophe Bélisle-Pipon As detailed in Part 1, Ontario government just enacted the Health Sector Payment Transparency Act, a Canadian first in terms of transparency. The act requires that “transfers of value” (or payments), related to medical products (drugs and medical devices), between a payor and a recipient be reported to the Health Ministry. The…
